Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cell Procurement

Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma

Bone Marrow Transplantation volume 42, pages 649–657 (2008)Cite this article

Abstract

The best method to mobilize PBSCs in patients with non-Hodgkin's Lymphoma (NHL) is uncertain. We hypothesized that PBSC mobilization using an intensive chemotherapy regimen would improve outcomes after autologous hematopoietic stem cell transplantation (ASCT) in NHL patients at high risk for relapse. Fifty NHL patients were prospectively allocated to intense mobilization with high-dose etoposide plus either high-dose cytarabine or CY if they were ‘high risk’ for relapse, whereas 30 patients were allocated to nonintense mobilization with CY if they were ‘standard risk’ (all patients, ±rituximab). All intensely mobilized patients were hospitalized compared with one-third of nonintensely mobilized patients. The EFS after ASCT was the same between the two groups, but overall survival (OS) was better for intensely mobilized patients (<0.01), including the diffuse large B-cell subgroup (P<0.04). We conclude that the intense mobilization of PBSCs in patients with NHL is more efficient than nonintense mobilization, but with greater toxicity. The equalization of EFS and superiority of OS in patients intensely mobilized to those nonintensely mobilized suggests that a treatment strategy using intensive chemotherapy for mobilization may be improving NHL outcomes after ASCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  Google Scholar 

  2. Damon L, Rugo H, Tolaney S, Navarro W, Martin III T, Ries C et al. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Biol Blood Marrow Transplant 2006; 12: 316–324.

    Article  CAS  Google Scholar 

  3. Linker CA, Ries CA, Damon LE, Sayre P, Navarro W, Rugo HS et al. Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biol Blood Marrow Transplant 2000; 6: 50–57.

    Article  CAS  Google Scholar 

  4. Damon L, Johnson J, Niedzwiecki D, Cheson BD, Hurd D, Bartlett N et al. Immuno-chemotherapy (IC) and autologous stem cell transplant (ASCT) for untreated patients (pts) with mantle cell lymphoma (MCL): CALGB 59909. Blood 2006; 108: 774a (abst 2737).

    Article  Google Scholar 

  5. Negrin RS, Kusnierz-Glaz CR, Still BJ, Schrober JR, Chao NJ, Long GD et al. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood 1995; 85: 3334–3341.

    CAS  PubMed  Google Scholar 

  6. Negrin RS, Kiem HP, Schmidt-Wolf IG, Blume KG, Clearly ML . Use of the polymerase chain reaction to monitor the effectiveness of ex vivo tumor cell purging. Blood 1991; 77: 654–660.

    CAS  PubMed  Google Scholar 

  7. Flinn IW, O'Donnell PV, Goodrich A, Vogelsang G, Abrams R, Noga S et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6: 628–632.

    Article  CAS  Google Scholar 

  8. Arcaini L, Orlandi E, Alessandrino EP, Iacono I, Brusamolino E, Bonfichi M et al. A model of in vivo purging with rituximab and high-dose AraC in follicular and mantle cell lymphoma. Bone Marrow Transplant 2004; 34: 175–179.

    Article  CAS  Google Scholar 

  9. Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA . High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 1997; 15: 833–839.

    Article  CAS  Google Scholar 

  10. Stockerl-Goldstein KE, Horning SJ, Negrin RS, Chao NJ, Hu WW, Long GD et al. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 1996; 2: 76–85.

    CAS  PubMed  Google Scholar 

  11. Rebulla P, Finazzi G, Marangoni F, Avvisati G, Guliotta L, Tognani G et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 1997; 337: 1870–1875.

    Article  CAS  Google Scholar 

  12. Cao TM, Negrin RS, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Taylor TL et al. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000; 6: 387–394.

    Article  CAS  Google Scholar 

  13. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244–1253.

    Article  CAS  Google Scholar 

  14. Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068–3076.

    CAS  PubMed  Google Scholar 

  15. Hanania EG, Kavanagh J, Hortobagyi G, Giles RE, Champlin R, Deisseroth AB . Recent advances in the application of gene therapy to human disease. Am J Med 1995; 99: 537–552.

    Article  CAS  Google Scholar 

  16. Bachier CR, Giles RE, Ellerson D, Hanania EG, Garcia-Sanchez F, Andreeff M et al. Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma. Leuk Lymphoma 1999; 32: 279–288.

    Article  CAS  Google Scholar 

  17. Alici E, Björkstrand B, Treschow A, Aints A, Smith CI, Gahrton G et al. Long-term follow-up of gene-marked CD34+ cells after autologous stem cell transplantation for multiple myeloma. Cancer Gene Ther 2007; 14: 227–232.

    Article  CAS  Google Scholar 

  18. Fitoussi O, Simon D, Brice P, Makke J, Scrobohaci ML, Bibi Triki T et al. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 1999; 24: 747–755.

    Article  CAS  Google Scholar 

  19. Ballestrero A, Clavio M, Ferrando F, Gonella R, Garuti A, Sessarego M et al. High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma. Int J Oncol 2000; 17: 1007–1013.

    CAS  PubMed  Google Scholar 

  20. Haioun C, Mounier N, Quesnel B, Morel P, Rieux C, Beaujen F et al. Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: a pilot study of 36 patients. Ann Oncol 2001; 12: 1749–1755.

    Article  CAS  Google Scholar 

  21. Le Gouill S, Moreau P, Morineau N, Harousseau JL, Milpied N . Tandem high-dose therapy followed by autologous stem-cell transplantation for refractory or relapsed high grade non-Hodgkin's lymphoma with poor prognosis factors: a prospective pilot study. Haematologica 2002; 87: 333–334.

    PubMed  Google Scholar 

  22. Ahmed T, Rashid K, Waheed F, Kancherla R, Qureshi Z, Hoang A et al. Long-term survival of patients with resistant lymphoma treated with tandem stem cell transplant. Leuk Lymphoma 2005; 46: 405–414.

    Article  CAS  Google Scholar 

  23. Glossmann JP, Staak JO, Nogova L, Diehl V, Scheid C, Kisro J et al. Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma. Ann Hematol 2005; 84: 517–525.

    Article  CAS  Google Scholar 

  24. Papadopoulos KP, Noguera-Irizarry W, Wiebe L, Hesdorffer CS, Garvin J, Nichols GL et al. Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphoma. Bone Marrow Transplant 2005; 36: 491–497.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, University of California, San Francisco, CA, USA

    L Damon, L E Damon, K Gaensler, L Kaplan, T Martin III, J Rubenstein & C Linker

Authors
  1. L Damon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L E Damon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Gaensler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Kaplan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Martin III
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Rubenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Linker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Damon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Damon, L., Damon, L., Gaensler, K. et al. Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. Bone Marrow Transplant 42, 649–657 (2008). https://doi.org/10.1038/bmt.2008.236

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.236

Keywords

Search

Advanced search

Quick links